Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Fine tuning brings its own risks

Fine tuning brings its own risks

The FDA's decisions to halt and restart - all within one week - ProCyte Corp.'s Phase III trials of its Iamin peptide-copper compound to treat diabetic foot ulcers illustrates one of the tradeoffs in pivotal trial design - generating greater

Read the full 471 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers